3D Global Biotech is set to initiate its IPO process, with plans to submit an application for listing on the Taiwan Innovation Board or over-the-counter (OTC) market as early as the third quarter. Targeting opportunities in the ocular health market, the company leverages its proprietary nano-surface functional crosslinking technology to enhance the water content and moisture retention of contact lenses. Following its initial shipments of adult contact lenses to clients in China at the end of last year, 3D Global Biotech will also introduce orthokeratology lenses for pediatric myopia control, with shipments to China expected in the second half of the year.
Revenue for the first five months of 2025 reached NT$92.63 million, marking a tenfold year-over-year increase. This strong growth was driven primarily by technology licensing income and contributions from CDMO (Contract Development and Manufacturing Organization) collaborations involving exosome raw materials. In June last year, 3D Global Biotech signed an exclusive licensing agreement with Yung Ding Biotech for limbal stem cells (LSCs) and related proprietary technologies. The two companies are jointly developing LSC-derived exosome applications for use in medical devices, new drug candidates, and skincare products. The total contract value stands at US$5 million (approximately NT$164 million), and licensing income continues to be recognized as documentation is delivered in phases. Further contributions are expected throughout the second half of the year.
On the contact lens front, 3D Global Biotech’s nano-surface crosslinking technology enables the grafting and coating of active factors, allowing for the production of high-moisture, high-water-content lenses. Approximately 140,000 boxes were shipped to Chinese clients in November 2024. The company is now extending its product line into pediatric orthokeratology lenses, with shipments scheduled for the second half of 2025.
Additionally, other technology transfer agreements are under negotiation. On the CDMO side, development projects for medical devices such as dental implants and cardiovascular stents are underway and are expected to reach completion and contribute to revenue in the second half of the year. With diversified growth drivers—including licensing income, CDMO collaborations, and the expansion into pediatric contact lenses—3D Global Biotech anticipates significant revenue growth in the coming months.
At its recent shareholders’ meeting, the company approved a capital increase via a cash issuance of common shares to facilitate public underwriting ahead of its planned listing. Existing shareholders have waived their preemptive rights, officially initiating the IPO process. The company expects to submit its listing application as early as Q3.
Resource: 三鼎上市櫃申請Q3將啟動，切入兒童近視控制，下半年業績拚跳高
